Search Orphan Drug Designations and Approvals
-
| Generic Name: | Heterodimeric multi-specific IgG1 antibody targeting human epidermal growth factor receptor 2 (HER2) and NKG2D on natural killer (NK) and cytotoxic T-cells |
|---|---|
| Date Designated: | 10/25/2021 |
| Orphan Designation: | Treatment of Esophageal Cancer |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Dragonfly Therapeutics, Inc. 35 Gatehouse Drive Waltham, Massachusetts 02451 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







